EM1803F “Racing Toward a Cure for Blood Cancers with New CARs (CAR-T Cell Therapy)” (IM GR-030918)
The goal of this discussion is to review the use of Chimeric Antigen Receptor (CAR) TCell Therapy in Hematologic Malignancies.
UT Southwestern faculty, fellows, residents and medical students, community physicians, nurse clinicians, physician assistants and nurses.
At the conclusion of this activity, the participant should be able to:
- Describe the basic principles of how CAR T-Cell therapy is used to target cancer.
- Identify 2 diseases that can be treated by FDA approved versions of CAR T-Cell Therapy.
- Understand the toxicities and limitations of CAR T-Cell therapy.
- Review emerging data regarding the use of CAR T-Cell therapy in Multiple Myeloma.
Larry Anderson, Jr., M.D., Ph.D.
Associate Professor of Internal Medicine
Director of Myeloma, Waldenstrom’s, and Amyloidosis Program
Division of Hematology / Oncology
- 1.00 AMA